Drug intelligence / Profile preview

Ipsu oral gel

Development stage: Unknown
Lead developer: Camurus
Modality: Device-based Delivery → Drug Delivery Systems
Administration: Topical (oral)

Overview

Ipsu oral gel is a lipid-based, preservative-free oral gel designed to alleviate pain and promote healing of oral mucositis and ulcers caused by chemotherapy and radiotherapy. It functions by forming a protective mechanical film over the affected oral mucosa, thereby reducing irritation, improving the ability to eat, and facilitating the healing process. The product utilizes Camurus AB's patented FluidCrystal® technology. It was first launched in Europe in 2009 and has since been registered and marketed in various countries, including the US, Europe, Israel, and Japan. It received approval in China in February 2019 and became available in the market in July 2019.

Brand names: Ipsu益普舒
Other names: 益普舒口腔凝胶

Beyond the preview

Go deeper on Ipsu oral gel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ipsu oral gel.

Explore the full profile